LY3463251 is the first GDF-15 receptor agonist to complete a Phase I clinical trial, with results showing an average weight reduction of 3% in patients after 12 weeks of treatment
Our team also spent more than 1,300 hours studying clinical research into how CoQ10 can affect various bodily systems, including heart health, cognition, and fertility
Principal Scientist, Regeneron, Jay Caplan, President and Founder, Fractyl Health, Jerry Colca, Chief Scientific Officer, Cirius Therapeutics, Johan Fredrik Paulsson, Director Incretin and Amylin Biology, Novo Nordisk, Mina Sooch, Founder and General Partner, Apjohn Ventures, Scott Harris, Chief Medical Officer, Altimmune, Zohar Barbash, Chief Technology Officer, Lembas Bio Saturday, Aug 01, 2026 10:00a Atlantic Wharf Saturday, Jul 25, 2026 goes until 07/26 Davis Square Plaza Saturday, Jul 25, 2026 2:00p Jason Russell House Saturday, Aug 01, 2026 6:00p John F
In rat models of quadriceps detachment, BPC-157 accelerated myotendinous and muscle-to-bone junction repair, restoring full muscle function
